Allergan announces acquisition of Akarna Therapeutics
Allergan Inc. recently announced the acquisition of Akarna Therapeutics for an upfront payment of $50 million. Read More »
Allergan Inc. recently announced the acquisition of Akarna Therapeutics for an upfront payment of $50 million. Read More »
Abbott announced this week that its FreeStyle Libre Pro system, a groundbreaking continuous glucose monitoring (CGM) system designed for patients with diabetes, has been approved by the U.S. Food and Drug Administration (FDA).re Read More »
Perrigo Co. this week announced that it has agreed to an exclusive licensing agreement with Highland Pharmaceuticals LLC for its methamphetamine (meth) blocking technology called Tarex. Read More »
Jazz Pharmaceuticals plc recently reported that enrollment for its two Phase 3 clinical trials for JZP-110 has been finalized. Read More »
Amgen recently reported top-line results of its Phase 3 CLARION trial that was designed to assess KYPROLIS (carfilzomib), melphalan and prednisone (KMP), Amgen's new investigational regimen, while comparing it to Velcade (bortezomib). Read More »
Tarix Orphan LLC recently announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Status to TXA127, the company’s prospective treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin disorder. Read More »
Armetheon Inc., a specialty pharmaceutical company that focuses on the development of novel small molecule drugs for the treatment of cardiovascular diseases, recently released the results of its Phase 1 clinical trial assessing how the pharmacokinetics (PK) of tecarfarin and of warfarin is affected by severe chronic kidney disease (CKD). Read More »
Allergen plc recently announced that NAMZARIC is now available through prescription in pharmacies across the United States. Read More »
Mylan N.V. and Biocon Ltd. recently announced that Mylan’s Marketing Authorization Application (MAA) for Trastuzumab has been accepted by the European Medicines Agency (EMA) for review. Read More »
PharmaMar recently submitted a Marketing Authorization Application (MAA) for Aplidin to the European Medicines Agency (EMA). Read More »
Mark Merritt, president and CEO of the Pharmaceutical Care Management Association (PCMA), recently testified before the House Judiciary Subcommittee on Regulatory Reform, Commercial and Antitrust Law. Read More »
Meridian Bioscience Inc. has officially launched its Analyte Specific Reagent (ASR) line of products. Read More »
Medivir AB announced last week the release of new data from its Phase IIa MIV-711-201 trial. Read More »
Faraday Pharmaceuticals recently announced the start of its FDY-5301 Phase 1 clinical study, which is designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of FDY-5301, the company’s lead compound. Read More »
Portola Pharmaceuticals Inc. recently announced it has submitted a Marketing Authorization Application (MAA) for IndexXa to the European Medicines Agency, noting that the validation period has been completed and it has been accepted for review. Read More »
AbbVie recently released new data from its Phase 3 GARNET study involving the combination of VIEKIRAX and EXVIERA that shows significant response rates after only eight weeks of the medication. Read More »
AcelRx Pharmaceuticals Inc. recently presented the subgroup analysis from the SAP301 clinical study by board-certified plastic surgeon and AcelRx clinical investigator Dr. Shankar Lakshman at the American Society of Plastic Surgeons (ASPS) annual meeting. Read More »
Johnson & Johnson recently made a five-year commitment to aid the United Nations Sustainable Development Goals in its mission to see the improvement of the health and well-being of people worldwide. Read More »
Neuraltus Pharmaceuticals Inc. recently announced that it has begun a second Phase 2 trial of NP001, its investigational treatment designed for patients who have amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease. Read More »
Akcea Therapeutics, an Ionis Pharmaceuticals subsidiary, recently reported that significant results from two clinical studies of INOIS-APO(a) and IONIS-APO(a)-L have been published in The Lancet. Read More »